Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.5 GBX | 0.00% | 0.00% | +9.52% |
04-17 | Bivictrix granted FDA orphan drug status for rare cancer treatment | AN |
04-17 | BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment | MT |
Sales 2023 * | - | Sales 2024 * | - | Capitalization | 9.49M 11.87M 949M |
---|---|---|---|---|---|
Net income 2023 * | -11M -13.76M -1.1B | Net income 2024 * | -17M -21.27M -1.7B | EV / Sales 2023 * | - |
Net Debt 2023 * | 10.76M 13.46M 1.08B | Net Debt 2024 * | 28.9M 36.15M 2.89B | EV / Sales 2024 * | - |
P/E ratio 2023 * |
-0.65
x | P/E ratio 2024 * |
-0.45
x | Employees | 17 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 63.35% |
Current month | +2.22% | ||
1 month | +2.22% | ||
6 months | -11.54% | ||
Current year | +9.52% |
Managers | Title | Age | Since |
---|---|---|---|
Tiffany Thorn
FOU | Founder | 37 | 31/12/15 |
Adrian Howd
DFI | Director of Finance/CFO | 52 | 02/10/23 |
Simon Wallwork
SEC | Corporate Secretary | - | 21/06/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Kauffman
CHM | Chairman | 60 | 15/01/22 |
William Paris
BRD | Director/Board Member | 73 | 21/09/21 |
Susan Lowther
BRD | Director/Board Member | 65 | 21/09/21 |
Date | Price | Change | Volume |
---|---|---|---|
01/05/24 | 11.5 | 0.00% | 0 |
30/04/24 | 11.5 | 0.00% | 0 |
29/04/24 | 11.5 | 0.00% | 0 |
26/04/24 | 11.5 | 0.00% | 0 |
25/04/24 | 11.5 | 0.00% | 0 |
Delayed Quote London S.E., May 01, 2024 at 04:35 pm
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+9.52% | 11.89M | |
+1.53% | 42.19B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+7.15% | 24.63B | |
-21.50% | 18.2B | |
+30.71% | 12.01B | |
-0.55% | 11.76B | |
+15.75% | 10.4B | |
-3.68% | 9.94B |
- Stock Market
- Equities
- BVX Stock